Cervical cancer is one of the leading causes of cancer-related mortality among women. More than 99% of cervical cancers are rare complications of persistent infection of Human Papilloma Virus (HPV) over the span of years. The most affected age group was the postmenopausal group. Approximately 2–5% of the cases are diagnosed at 80 years and above as well, and most of these cases are associated with advanced disease not noted earlier. Microinvasive diseases are only identified on a cone biopsy sample. A punch biopsy is the preferred test for confirmation when there are visible lesions. The best radiological method for evaluating tumors larger than 10 mm is magnetic resonance imaging. It takes approximately 15–20 years to progress into cancer from virus infection. It can be screened much before progression into cancer, and it is completely curable if it is caught in early stages and managed effectively even when it is found late. Correct staging of cervical cancer is crucial because it influences the prognosis of the patient and the kind of treatment (chemoradiation, surgery, or chemotherapy alone). Primary, secondary, and tertiary prevention are the three interrelated essential elements of comprehensive cervical cancer prevention and control.